• HOME
  • CONTACT US
Logo Logo Logo Logo Logo
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • HH INHIBITION WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • News Releases
    • Events & Presentations
    • Stock Information
      • Interactive Chart
      • Historical Price Lookup
    • Financials-Filings
      • SEC Filings
      • Fundamentals
      • Annual Reports – Proxy Satements
    • Corporate Governance
      • Committee Composition
    • Investor Resources
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • HH INHIBITION WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • News Releases
    • Events & Presentations
    • Stock Information
      • Interactive Chart
      • Historical Price Lookup
    • Financials-Filings
      • SEC Filings
      • Fundamentals
      • Annual Reports – Proxy Satements
    • Corporate Governance
      • Committee Composition
    • Investor Resources
Search:
 

Information Concerning Proposed Settlement of Litigation Concerning the Company

 

  • Notice of Pendency of Derivative and Class Actions, Proposed Settlement and Settlement Hearing
  • Stipulation and Agreement of Compromise, Settlement, and Release
  • Scheduling Order entered by the Delaware Court of Chancery
Inhibitor-Therapeutics

900 West Platt Street
Suite#200
Tampa, FL 33606-2173

Our Mission

Inhibitor Therapeutics, Inc. (“INHIBITOR”) is a pharmaceutical development company focused on developing and commercializing innovative therapies based on already approved active pharmaceutical ingredients for novel, clinically valuable, and patent-protected indications. Our lead product is itraconazole for a hereditary, cancer syndrome (Gorlin’s syndrome) which is an orphan disease.

  • Home
  • Who We Are
  • Pipeline
  • Investors & Media
  • Contact Us
  • Terms of Use and Privacy Policy

Copyright 2023 Inhibitor Therapeutics, Inc.